299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details

臨床試験数 : 1,696 / 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

16 trials found

diseases per page:

Showing 1 to 10 of 16 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05090904 (ClinicalTrials.gov)	November 30, 2021	14/10/2021	A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BrensocatibTablets in Adults Wit ...	A Phase 2a, Single-Blind, Placebo-Controlled, Parallel-Group Study to Assess Safety, Tolerability, a ...	Cystic Fibrosis	Drug: Brensocatib;Drug: Placebo	Insmed Incorporated	NULL	Recruiting	18 Years	N/A	All	48	Phase 2	United States
2	EUCTR2020-003688-25-SK (EUCTR)	01/06/2021	10/12/2020	A study to evaluate the effects of BrensocatibAdministered Once Daily for 52 Weeks in Subjects with ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and To ...	Non-Cystic Fibrosis Bronchiectasis MedDRA version: 23.0;Level: LLT;Classification code 10083611;Term ...	Product Name: Brensocatib Product Code: INS1007 INN or Proposed INN: Brensocatib Other descriptive name ...	Insmed Incorporated	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1660	Phase 3	Portugal;Serbia;United States;Estonia;Taiwan;Slovakia;Greece;Spain;Thailand;Ukraine;Ireland;Israel;C ...
3	JPRN-jRCT2031210048	30/04/2021	22/04/2021	A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatibin Participants With Non-Cyst ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and To ...	Non-Cystic Fibrosis Bronchiectasis	- Experimental: Brensocatib10 mg Participants will receive brensocatib10 mg once daily, for 52 weeks. ...	Fernandez C	NULL	Recruiting	>= 18age old	<= 85age old	Both	1620	Phase 3	United States;Canada;Germany;Australia;New Zealand;Taiwan;Japan
4	EUCTR2020-003688-25-DE (EUCTR)	08/04/2021	12/10/2020	A study to evaluate the effects of BrensocatibAdministered Once Daily for 52 Weeks in Subjects with ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and To ...	Non-Cystic Fibrosis Bronchiectasis MedDRA version: 23.0;Level: LLT;Classification code 10083611;Term ...	Product Name: Brensocatib Product Code: INS1007 INN or Proposed INN: Brensocatib Other descriptive name ...	Insmed Incorporated	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1620	Phase 3	Portugal;Serbia;United States;Taiwan;Estonia;Slovakia;Greece;Spain;Thailand;Ukraine;Ireland;Russian ...
5	EUCTR2020-003688-25-LT (EUCTR)	05/03/2021	07/12/2020	A study to evaluate the effects of BrensocatibAdministered Once Daily for 52 Weeks in Subjects with ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and To ...	Non-Cystic Fibrosis Bronchiectasis MedDRA version: 23.0;Level: LLT;Classification code 10083611;Term ...	Product Name: Brensocatib Product Code: INS1007 INN or Proposed INN: Brensocatib Other descriptive name ...	Insmed Incorporated	NULL	Not Recruiting			Female: yes Male: yes	1620	Phase 3	Portugal;Serbia;United States;Taiwan;Estonia;Slovakia;Greece;Spain;Thailand;Ukraine;Ireland;Russian ...
6	EUCTR2020-003688-25-EE (EUCTR)	01/03/2021	06/01/2021	A study to evaluate the effects of BrensocatibAdministered Once Daily for 52 Weeks in Subjects with ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and To ...	Non-Cystic Fibrosis Bronchiectasis MedDRA version: 23.0;Level: LLT;Classification code 10083611;Term ...	Product Name: Brensocatib Product Code: INS1007 INN or Proposed INN: Brensocatib Other descriptive name ...	Insmed Incorporated	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1620	Phase 3	Portugal;Serbia;United States;Estonia;Taiwan;Slovakia;Greece;Spain;Thailand;Ukraine;Ireland;Israel;C ...
7	EUCTR2020-003688-25-AT (EUCTR)	11/02/2021	10/12/2020	A study to evaluate the effects of BrensocatibAdministered Once Daily for 52 Weeks in Subjects with ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and To ...	Non-Cystic Fibrosis Bronchiectasis MedDRA version: 23.0;Level: LLT;Classification code 10083611;Term ...	Product Name: Brensocatib Product Code: INS1007 INN or Proposed INN: Brensocatib Other descriptive name ...	Insmed Incorporated	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1620	Phase 3	Portugal;Serbia;United States;Taiwan;Estonia;Slovakia;Greece;Spain;Thailand;Ukraine;Ireland;Russian ...
8	EUCTR2020-003688-25-BG (EUCTR)	27/01/2021	04/12/2020	A study to evaluate the effects of BrensocatibAdministered Once Daily for 52 Weeks in Subjects with ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and To ...	Non-Cystic Fibrosis Bronchiectasis MedDRA version: 23.0;Level: LLT;Classification code 10083611;Term ...	Product Name: Brensocatib Product Code: INS1007 INN or Proposed INN: Brensocatib Other descriptive name ...	Insmed Incorporated	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1660	Phase 3	United States;Serbia;Portugal;Taiwan;Estonia;Slovakia;Greece;Thailand;Spain;Ukraine;Ireland;Israel;C ...
9	EUCTR2020-003688-25-IE (EUCTR)	18/01/2021	30/10/2020	A study to evaluate the effects of BrensocatibAdministered Once Daily for 52 Weeks in Subjects with ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and To ...	Non-Cystic Fibrosis Bronchiectasis MedDRA version: 23.0;Level: LLT;Classification code 10083611;Term ...	Product Name: Brensocatib Product Code: INS1007 INN or Proposed INN: Brensocatib Other descriptive name ...	Insmed Incorporated	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1620	Phase 3	Portugal;Serbia;United States;Taiwan;Estonia;Slovakia;Greece;Spain;Thailand;Ukraine;Ireland;Russian ...
10	EUCTR2020-003688-25-BE (EUCTR)	15/01/2021	15/01/2021	A study to evaluate the effects of BrensocatibAdministered Once Daily for 52 Weeks in Subjects with ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and To ...	Non-Cystic Fibrosis Bronchiectasis MedDRA version: 23.0;Level: LLT;Classification code 10083611;Term ...	Product Name: Brensocatib Product Code: INS1007 INN or Proposed INN: Brensocatib Other descriptive name ...	Insmed Incorporated	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1620	Phase 3	United States;Serbia;Portugal;Taiwan;Estonia;Slovakia;Greece;Thailand;Spain;Ukraine;Ireland;Russian ...

First Previous1 2Next Last